{"id":978628,"date":"2026-07-06T09:58:13","date_gmt":"2026-07-06T13:58:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/"},"modified":"2026-07-06T09:58:13","modified_gmt":"2026-07-06T13:58:13","slug":"belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/","title":{"rendered":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium"},"content":{"rendered":"
\n

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Belite Bio<\/a>, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.<\/p>\n

\n Webcast Link Instructions<\/strong>
\n
A webcast of the presentation can be accessed under “Events” in the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events<\/a>. The replay will be archived for 90 days following the presentation date.<\/p>\n

\n About Belite Bio<\/strong>
\n
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio\u2019s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2\/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on\u00a0X<\/a>,\u00a0Instagram<\/a>,\u00a0LinkedIn<\/a>, and\u00a0Facebook<\/a>, or visit us at\u00a0www.belitebio.com<\/a>.<\/p>\n

\n Media and Investor Relations Contacts:<\/strong>
\n
\n Jennifer Wu\u00a0\/\u00a0<\/strong>
\n ir@belitebio.com<\/a>
\n
\n Argot Partners\u00a0\/\u00a0<\/strong>
\n belite@argotpartners.com<\/a>
\n \u00a0<\/strong>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET. Webcast Link Instructions A webcast of the presentation can be accessed under “Events” in the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replay will be archived for 90 days following the presentation date. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting … <\/p>\n

Continue reading “Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-978628","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBelite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET. Webcast Link Instructions A webcast of the presentation can be accessed under “Events” in the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replay will be archived for 90 days following the presentation date. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting … Continue reading "Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T13:58:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium\",\"datePublished\":\"2026-07-06T13:58:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/\",\"name\":\"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=\",\"datePublished\":\"2026-07-06T13:58:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk","og_description":"SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET. Webcast Link Instructions A webcast of the presentation can be accessed under “Events” in the investor relations section of the Belite Bio website at: https:\/\/investors.belitebio.com\/presentations-events\/events. The replay will be archived for 90 days following the presentation date. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting … Continue reading \"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-06T13:58:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium","datePublished":"2026-07-06T13:58:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/"},"wordCount":266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/","name":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=","datePublished":"2026-07-06T13:58:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NzE5MiM3NjkxNzM0IzIyMzM3MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/978628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=978628"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/978628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=978628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=978628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=978628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}